CA
CRNX icon

CoreCap Advisors’s Crinetics Pharmaceuticals CRNX Stock Holding History

CoreCap Advisors’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$524 Hold
14
– – ﹤0.01% 2848
2026
Q1 		$508 Hold
14
– – ﹤0.01% 2648
2025
Q4 		$652 Buy
+14
New +$623 ﹤0.01% 2664
2025
Q2 		– Sell
-7
Closed -$235 – 2872
2025
Q1 		$235 Buy
+7
New +$261 ﹤0.01% 2904

Other funds holding CRNX

MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
LAM
Lewis Asset Management Lafayette, California $285M AUM 32.52% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
BP
Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
AA
AlphaCentric Advisors San Juan, Puerto Rico $118M AUM

CoreCap Advisors's CRNX Position: Q2 2026 in Review

CoreCap Advisors held its Crinetics Pharmaceuticals (CRNX) position steady in Q2 2026 at 14 shares worth $524. The position accounts for ﹤0.01% of the portfolio, ranked #2848.

CoreCap Advisors first reported a position in CRNX in Q1 2025 and has held it in 4 quarters since. The position peaked at $652 in Q4 2025. 32 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • CoreCap Advisors held 14 shares of Crinetics Pharmaceuticals worth $524 as of Q2 2026.
  • CoreCap Advisors left its Crinetics Pharmaceuticals share count unchanged in Q2 2026.
  • Crinetics Pharmaceuticals made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #2848 holding.
  • CoreCap Advisors first reported a position in Crinetics Pharmaceuticals in Q1 2025 and has held it in 4 quarters since.
  • CoreCap Advisors's Crinetics Pharmaceuticals position peaked at $652 in Q4 2025.
  • 32 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.